Myriad myRisk® Soon To Be Even More Comprehensive

Analysis of HOXB13 added to Myriad myRisk® Hereditary Cancer Panel

Myriad Genetic Laboratories, Inc. is excited to announce the addition of full sequencing analysis of a new gene, HOXB13, to the Myriad myRisk® Hereditary Cancer Panel, planned for October 11, 2018.

The G84E (c.251G>A) variant in the HOXB13 gene is associated with an increased risk of prostate cancer that is significantly higher than the general population risk for prostate cancer.123  This HOXB13 variant has also been linked to prostate cancer occurring at an earlier age.3

At this time, no other variants in HOXB13 have been linked to an increased risk of prostate cancer, but myRisk testing will include full sequencing of the gene in order to accommodate new information about additional HOXB13 variants that impact patient care.

Each gene tested with Myriad myRisk links to one or more of eight cancer sites: Breast, Ovarian, Colorectal, Endometrial, Melanoma, Pancreatic, Gastric, and Prostate.

Myriad myRisk simplifies the test selection process by providing you the most comprehensive hereditary cancer panel test with clinically significant results. Be confident you are testing for the primary clinically significant genes associated with your patients’ risk

The National Comprehensive Cancer Network (NCCN) has recently issued updated guidelines regarding which men with a personal or family history of prostate cancer should consider undergoing genetic testing for BRCA1 and BRCA2, which are also included on the Myriad myRisk Hereditary Cancer panel. The new guidelines state that a variety of men should be considered for testing:

  • All men with high-risk, very high-risk, regional, or metastatic prostate cancer4
  • All men with high-grade prostate cancer (Gleason score ≥7) at any age and a family history5 consisting of
    • A close blood relative with ovarian, pancreatic, or metastatic prostate cancer at any age; or
    • A close blood relative with breast cancer <50 years of age; or
    • Two or more close blood relatives with breast or prostate cancer at any age
  • Patients with a first or second degree blood relative meeting the criteria directly above

Possible medical management recommendations6 for men with a higher risk of prostate cancer, such as those with a pathogenic HOXB13 variant, include:

  • Baseline PSA screening at age 40 years or 10 years prior to youngest prostate cancer diagnosed in family
  • Interval of screening yearly or determined by baseline PSA

Please check back periodically for more information as we prepare to add HOXB13 to the Myriad myRisk® Hereditary Cancer panel.

You may also reach out to your local Myriad Account Executive or Regional Medical Specialist, or call 1-800-4-MYRIAD (800-469-7423) for more information. For a full list of the genes currently included on Myriad myRisk, please view the Myriad myRisk® Gene Table.

1 Beebe-Dimmer, et al: Cancer Epidemiol Biomarkers Prev. 2015 Sep;24(9):1366-72. PMID: 26108461

2 Stott-Miller, et al: Prostate. 2013 May;73(6):634-41. PMID: 23129385

3 Witte, et al: Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):675-80. PMID: 23396964

4 Referenced with permission from the NCCN: Prostate Cancer. Version 3.2018. © National Comprehensive Cancer Network, Inc. 2018.

5 Referenced with permission from the NCCN: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2019. © National Comprehensive Cancer Network, Inc. 2018.

6 Giri VN, et al. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 36:414-424. PMID: 29236593.